The changes in cerebral blood flow that ac company spreading depression are well-described, as are parallel changes in cellular activity, with a wave of hy peremia followed by a prolonged oligemic phase, In this study, a cat model of the CBF changes associated with spreading depression and in vitro pharmacology were used to determine if there is a role for the powerful pep tide vasoconstrictor endothelin in this response, For the pharmacological studies, the middle cerebral artery was harvested from cats postmortem, For the physiological studies, cats were anesthetized with halothane induction and a-chloralose (60 mg/kg, intraperitoneal loading; 20 mg/kg i,v, 2-h maintenance), CBF was monitored contin uously in the parietal cortex using laser Doppler flow metry (CBFLDF) after exposure of the dura mater. The in vitro work demonstrated that endothelin-I (ET -I) medi ates a strong and potent contraction of cerebral vessels, Both the selective ETA receptor antagonist FRI39317 and the combined ETA and ET B receptor antagonist Bosentan caused a rightward shift of the concentration-response curve without attenuation of the maximum effect. The Abbreviations used: CBFLDF, cerebral blood flow with laser Doppler flowmetry; ET-1, endothelin-1; MCA, middle cerebral artery; SD, spreading depression.
Headache in its many manifestations and mi graine in particular make up a common and often debilitating clinical problem whose pathophysiol ogy has been the subject of considerable investiga tion (Goadsby, 1994) . Some 15% of patients with migraine describe a prodrome of neurological symp toms that are virtually characteristic of the condi tion (Bes et al., 1988) . This aura phase of migraine calculated pA2 values were 6,28 and 6,90, respectively, The slope did not differ from unity, suggesting that the ET-I-mediated contraction is evoked by a single popUla tion of ETA receptors, which were effectively antago nized by these compounds, Spreading depression was in duced with a needle stick injury to the cortex, Local ad ministration of the endothelin antagonists FR139317 (10 fLM) and Bosentan (10 fLM) did not affect resting blood flow in the cortex, Induction of spreading depression fol lowing local administration of FR139317 and Bosentan resulted in responses no different from those in control cortex, These data demonstrate that endothelin does not play a significant role in the vasoconstrictor portion of the CBF change seen in spreading depression, nor does it affect resting flow, Since it is widely held that spreading depression, or a very similar mechanism, underlies the aura phase of migraine, it may be suggested from these studies that endothelin antagonists are unlikely to be use ful in migraine, Key Words: Endothelin-Spreading de pression-FR 139317-Bosentan, has been the subject of considerable interest and has been proposed to be closely related to the spreading depression (SD) of Leao (1944) . This as sociation has resulted in considerable interest in the mediation of SD and possible avenues by which the phenomenon can be modulated.
The aura phase of migraine is characterized by various neurological symptoms that have particular features. Patients report phenomena such as pho topsia (shimmering edges of moving light), scoto mata (areas of loss of vision), limb paraesthesia, vertigo, and diplopia (double vision). The symp toms generally move across the visual field or limb in an orderly slow march. Lashley (1941) , in his now classic paper, described the progress of his own aura by plotting its movement and shape as it traversed his visual field. There is considerable cir cumstantial evidence linking SD with the aura phase of migraine. Numerous studies have con firmed that the aura phase of migraine is associated with a reduction in CBF (Skinhoj and Paulson, 1969; O'Brien, 1971; Simard and Paulson, 1973; Skinhoj, 1973; Norris et aI., 1975; Mathew et aI., 1976; Edmeads, 1977; Hachinski et aI., 1977; Sakai and Meyer, 1978; Olesen et aI., 1981; Staehelin Jensen et aI., 1981; Lauritzen et aI., 1983a; Lau ritzen and Olesen, 1984; Skyhoj-Olsen et aI., 1987) . The visual aura and other focal neurological signs, when they are present, are often associated with this reduction in CBF (Olesen et aI., 1981) . In some cases, there is clear documentation of a dissociation between the aura and the headache (Olesen et aI., 1990) . The neurological changes parallel what is seen when the brain is directly stimulated (Brindley and Lewin, 1968; Penfield and Perot, 1963) and re semble what might be predicted if ocular dominance columns (Hubel and Weisel, 1968) were serially ac tivated. The change in flow moves across the cortex as a spreading oligemia at 2-3 mm/min (Lauritzen et aI., 1983a; Lauritzen and Olesen, 1984) , corre sponding to the rate that Lashley (1941) 
Supporting the association of migraine and SD are reports that the oligemia is preceded by a phase of focal hyperemia (Olesen et aI., 1981; Friberg et aI., 1987) . Such a change is exactly what would be expected if a phenomenon similar to cortical SD was involved. Following the passage of the oligemia, the cerebrovascular response to hyper capnia is blunted (Simard and Paulson, 1973; Sakai and Meyer, 1979; Harer and von Kummer, 1991) , while autoregulation remains intact (Lauritzen et aI., 1983b) . Again, this pattern is repeated in SD. It has also been shown in the experimental animal that initiation of SD results in subcortical reductions in blood flow even in anatomically distant areas in the brain stem (Mraovitch et aI., 1992) . Furthermore, it has been shown that the vasodilator phase of SD, at least in the cat, involves generation of nitric oxide since the neurophysiological correlates of SD can be dissociated from the hyperemic phase by nitric oxide synthesis inhibitors (Goadsby et aI., 1992) . A similar blunting of the vasodilator phase has been seen in the rat (Duckrow, 1993) , although a recent contradictory report (Zhang et aI., 1994) suggests there is more to understand in relationship to the vasodilator phase.
Endothelin-I (ET -I) is the most powerful vaso constrictor substance currently described. It is a low-molecular-weight polypeptide secreted by cul tured endothelial cells from cerebral vessels. The advent of antagonists of the action of ET -1 (Sogabe et aI., 1993; Clozel et aI., 1994) provides tools with which to determine what role this peptide may have in vasoconstrictor responses in the cerebral circu lation. In this study, we characterized the ET -1 re ceptor mediating contraction in the cerebral vessels and thus determined the optimum pharmacological variables with which to evaluate whether an ET-l antagonist can alter the oligemic phase of SD. Since it has been shown that ET -1 levels are increased in the plasma of people with migraines (Farkkila et aI., 1992; Gallai et aI., 1994) , the fundamental question arises as to whether ET -I mediates the vasocon strictor phase of SD.
METHODS

In vitro pharmacology
Young adult cats (mean weight, 4.4 kg) were anaesthe tized with a-chloralose and exsanguinated. The brain was rapidly removed and immersed in a 37°C buffer solution continuously aerated with 5% CO2 in 02' The middle ce rebral artery (MCA) was dissected free from tissue under an operating microscope and cut into smaller circular seg ments (1 mm long). For examination, each segment was mounted on two L-shaped metal prongs (0.1 mm in diam eter), one of which was connected to a force displacement transducer (FT03C) attached to a MacLab unit for continuous recording of the isometric tension. The position of the other holder could be changed by means of a movable unit, allowing fine adjustments of the vascular tension by varying the distance between the met al prongs (Adner et ai., 1993) .
The specimens were immersed in temperature controlled (37°C) tissue baths containing a buffer solution of the following composition (mM): NaCl, 119; NaHC03, 15; KCI, 4.6; MgCI2, 1.2; NaH2P04, 1.2; CaCI2, 1.5; glu cose, 11. The solution was continuously aerated with car bogen gas, giving a pH of 7.4. A tension of 2 mN was applied to the arterial segments, and they were allowed to stabilize at this level of tension for 1 h. The contractile capacity of each vessel segment was examined by expo sure to a potassium rich (60 mM) buffer solution that had the same composition as the standard buffer solution ex cept that some of the NaCI was exchanged for an equi molar concentration of KCI. This resulted in a contrac tion of 3.34 ± 0.53 mN (n = 19). The effect of endothelin was examined by cumulative application of ET-l (0.1 pM to 1 fLM).
-propionyl]]-amino-3-(2-pydridyl) proprionic acid; Fujisawa Pharmaceutical, Osaka, Japan), and Bose ntan (4-t e rtbuty 1-N -[ 6-(2-hydroxy -etho xy )-5-(2methox y -phenoxy)-2,2' -bipyrimidin-4-y l]-bezenesulf onamide; Ro 47-0203; Roche, Switzerland) were dis solved in distilled water containing 1 % bovine serum al bumin. All other compounds were obtained from Sigma. For the experiments, the drugs were further diluted in buffer solution or saline.
Calculations for in vitro work. The data from the con centration-response curves were characterized by Emax values (maximum contractile effect as a percentage of the effect of 60 mM K + -buffer solution) and pD2 values (neg ative logarithm of the molar concentration that produced half-maximum contraction). The pA2 value (negative log arithm of the molar concentration of the antagonist that reduces the effect of the agonist to half the dose) analysis was done as described by Tallarida and colleagues (1979) . To compare the difference between treatment and con trols, Wilcoxon signed-rank test was used on in vitro data with p < 0.05 considered to be significant.
Cerebral blood flow
Cats weighing 2.7 ± 0.3 kg (mean ± SD) were anesthe tised with u-choloralose (60 mg/kg, i.p., with supplements of 20 mg/kg i. v.) after induction with 4% halothane. They were intubated and ventilated (Harvard Pump, MA, U.S.A.) and paralyzed with gallamine triethiodide (6 mg/ kg, i. v.). End-expiratory CO2 and fraction of inspired O2 were continuously monitored (Datex, Finland). Polyeth ylene catheters were placed into the femoral artery for monitoring blood pressure and into the vein for fluid and drug administration.
Cerebral blood flow with laser Doppler flow me try . Ce rebral cortical perfusion was measured continuously us ing laser Doppler flowmetry (LDF). The principles of op eration of LDF have been thoroughly described (Stern et aI., 1977) , and its use in this laboratory has been de scribed in detail (Goadsby, 1991) . Briefly, infrared light from a laser diode with a wavelength 0[780 nm is directed to the surface of the brain via a fiber optic cable. Analysis of the Doppler shift caused by that portion of light scat tered by the red blood cells gives the velocity of flow for those cells, while the proportion of light backscattered is directly related to the volume of moving red cells in the brain sampled. A flow index can thus be derived from these signals. In these experiments, the BPM 403A (TSI, MN, U.S.A.) instrument was used with a pencil probe (P-433, TSI) mounted in a stereotaxic manipulator (David Kopf Instruments, CA, U.S.A.) and the signals for flow, velocity, and volume were continuously monitored. Bi parietal craniotomies were carried out with a low-speed dental drill that was cooled with saline to prevent under lying thermal injury, and the dura was left intact under the probe although it was cut adjacent for drug administra tion. Cerebrovascular reactivity to a brief period of hy percapnia (6-8%) was tested before collecting data and during the experiment as part of the protocol.
To determine accurately the changes in cerebrovascu lar dynamics measured with the laser Doppler, the phys iological variables were monitored on-line by a micro computer. The blood pressure, heart rate, end-expiratory CO2, inspiratory 02' and laser Doppler volume, flow, and velocity signals were passed to a signal-conditioning de vice and then to an analog-to-digital convertor (LabMas ter DMA, Scientific Solutions, OH, U.S.A.) in an 80386/ 80387-based microcomputer. Signals were continuously monitored and displayed on the computer screen using locally written software in C language. All data were stored on disk for later analysis and plotting.
Surgery and stimulation. The animals were placed in a stereotaxic frame (Kopf, Tujunja, CA, U.S.A.), primar ily to facilitate the measurement of CBF with LDF (CBFLDF). The parietal cortex and overlying dura mater were exposed bilaterally. The bone was carefully drilled away using a low-speed dental drill and saline irrigation. The area was exposed over some 15 mm to allow access for the stimulating needle. Spreading depression was in-J Cereb Blood Flow Metab. Vol. 16, No.4. 1996 duced with a 23-gauge needle lowered in a stereotaxic holder to a distance of 5 mm into the brain and then removed.
Experimental design and statistics. We (Goadsby et aI., 1992; Kaube and Goadsby, 1994) and others (Duck row and Beard, 1992) have seen that in some circum stances the oligemic phase of SD depends to a great ex tent on the resting CBF and particularly on whether SD has been previously induced. Whether a SD has been induced can be determined by testing for the CBFLDF hypercapnic response, which is known to be blocked af ter passage SD (Lauritzen et ai, 1983b) . When SD has been induced, the oligemic phase is generally not seen on subsequent inductions. In this study, the animals were compared left to right so that one of either side had FRJ39317 (10 JLM) or Bosentan (10 JLM), and the other side had vehicle administered; SD was then elicited on each side. The blockade was tested first by locally inject ing a glass micropipette of ET-l and reapplying the pep tide after local application of the antagonist. Local appli cation of ET-l (10-8 M) produced a vasoconstriction, with a 37 ± 7% reduction in CBFLDF.
The CBF LDF data were transformed to percentages of change from the control period (Kaiser, 1989) to allow for animal-to-animal variation and expressed as mean ± SD. Data were compared using a Mann-Whitney V test (Sie gel, 1956 ) and assessed at the p < 0.05 level for signifi cance.
RESULTS
In vitro pharmacology
ET-I produced strong and potent concentration dependent contractions of cat MCA (Fig. 1) . The Emax was 115 ± 39% relative to potassium contrac tion and potency, and pD2 was 8.42 ± 0.07. FR 139317 (1 and 10 /-LM) had no contractile effect by itself but caused a shift to the right of the ET-l concentration-response curve (pD2 was 7.87 ± 0.38 and 6.96 ± 0.21, respectively) without changing the maximum contractile response ( Fig. 1; Table 1 ). Schild plot analysis resulted in a pA2 value of 6.28 with a slope of 1. 12 (not different from unity). Sim ilarly, Bosentan had no contractile effect alone but caused a shift to the right of the ET -I dose-response curve at all concentrations (0.1, 1, and 10 /-LM) stud ied. The Schild plot analysis of Bosentan demon strated a slope of 0.90 and a pA2 of 6.90 (Fig. 2) , showing a greater potency than seen with FR 139317.
Spreading depression
All nine animals included in the analysis had blood pressure, heart rate, and respiratory blood gas data within normal limits for the anesthetized cat.
CBFLDF. Local administration of FR139317 (10 /-LM) did not alter CBFLD F (8 ± 10%; not signifi cant), but it did block the vasoconstrictor response to ET-I (10-8 M; p < 0.05; n = 5). On the control side, needle stick induction of SD resulted in an initial vasodilator phase, with a 263 ± 61 % increase in CBFLDF followed by a 21 ± 13% reduction in flow . Following administration of FR 139317 (10 fLM), induction of SD resulted in a 276 ± 65% in crease in CBFLDF and a 20 ± 12% reduction in the oligemic phase (Fig. 3) . Neither response was af fected by the presence of FR139317 (n = 5; Fig. 4 ).
In a further series of experiments, Bosentan (10 fLM) similarly failed to attenuate the hyperemic or oligemic phases of SD (n = 4; Fig. 5 ).
DISCUSSION
These data have demonstrated that ET -1 is a strong and potent constrictor of cat cerebral ves sels. This vasoconstriction was competitively blocked by the nonpeptide compounds FR139317 and Bosentan. Furthermore, blockade of endothelin receptors with two potent endothelin antagonists did not alter any aspect of the vascular manifesta tions of SD. The data demonstrate that neither the vasodilator nor oligemic phases of SD were affected by endothelin blockade, even in the presence of doses of antagonists that block the effects of exog enous ET -1. These results suggest that endothelin might not be expected to have a role in pathophys iological settings in which SD is thought to be acti vated.
The data presented here for FR 139317 and Bosentan are consistent with findings in other vas cular beds that this compound is an effective endo thelin ETA receptor antagonist. Although Bosentan has some activity as an antagonist at the ET B re ceptor, the data, taken together with those in the literature, suggest the ETA receptor as the main site for the cerebral circulation. This is in contrast to the lack of effect of FR 139317 in models in which the endothelin ET B receptor is activated (McMurdo et aI., 1993; Sudjarwo et aI., 1993) . The pA2 in the MCA is most like that of the guinea pig pulmonary artery (pA2 = 6.65) (Cardell et aI., 1993) and dif fers from findings in other vascular beds, such as the guinea pig isolated iliac artery (pA2 = 5.82) (Schoeffter et aI., 1993) . At the concentrations of FR139317 and Bosentan used in the physiological study, it would be expected that any role for the ETA receptor in SD would have been revealed. In deed, the positive control in this study (demonstrat ing in vivo that the vasoconstrictor response to ex ogenous ET -1 could be eliminated) confirms that biologically relevant concentrations of the antago nists were used. Moreover, FR139317 has been shown in another pathophysiological setting, exper imental subarachnoid hemorrhage, to reduce endo thelin-mediated vasoconstriction . A role for endothelin in the mediation of va sospasm has thus been postulated.
The primary objective of this study was to deter- mine if there is a role for the endothelin ETA recep tor in the oligemic phase of SD. This receptor site was chosen because of the clear demonstration in pharmacological studies that the ETA receptor is the dominant receptor in the cerebral circulation (Adner et al., 1993) and in view of the suggestion of a possible role for endothelin during migraine (Ed meads, 1991; Farkkila et al., 1992; Gallai et al., 1994) . The cerebral circulatory changes associated with SD have been well-characterized. The first phase is a marked hyperemic phase, which is fol lowed by a more prolonged oligemic phase (Lau ritzen et aI., 1982; Lacombe et al., 1992) . In addi- tion, cortical hypercapnic responses are blocked (Lauritzen, 1984) , while autoregulation may (Flor ence et aI., 1994) or may not (Lauritzen, 1984) be impaired. The oligemic phase is thought to be the pathophysiological substrate for the neurologically negative symptoms of migraine, such as scotoma and hemiparesis. This interpretation may, however, need to be widened. Recent positron emission to mography data carefully documented a patient with a migraine who had no aura yet had what would be regarded as a classical wave of spreading oligemia (Woods et aI., 1994) . These new data, albeit from a single case, are compelling enough to require fur ther experimental study of this phenomenon. Can a SD occur without major neurological symptoms? The design of our study was important to the interpretation of the results. We used the cortex in a paired fashion, with one side receiving antagonist and the other vehicle. This approach was necessary since in our model induction of SD usu ally blocks or inhibits subsequent oligemia as mea sured with LDF, even though further hyperemias are relatively easy to induce. Care not to induce SD during the preparatory surgery was crucial since this would result in false-positive blockade of the oligemic phase. We (Goadsby, 1992) and others (Duckrow and Beard, 1992) have addressed this is sue previously to examine the role, if any, of free radical generation in the oligemic response (Hall and Smith, 1991) .
In summary, these data demonstrate that ET-1 mediates a strong and potent constriction of cat ce rebral vessels. The selective ETA receptor antago nist FR 139317 and the ETA and ET B antagonist Bosentan competitively antagonized the ET -1evoked contraction, suggesting that it is mediated through a single population of ET A receptors. These data suggest, since doses of FR139317 and Bosen tan capable of blocking endothelin-mediated effects do not block the oligemic phase of SD, that neither ETA nor ET B receptors mediate this phenomenon. If SD or a closely homologous human process is the pathophysiological substrate for the neurological disturbance in migraine with aura, then such com pounds are unlikely to alter the course of migraine headache. The ultimate test of this view will be clin ical studies in patients with aura. These data predict that such studies will demonstrate no effect of en dothelin antagonists in migraine.
